|

Liver Disease Clinical Trials in Indianapolis, IN

30 recruiting studies within 50 miles

Phase
Trial Phase Dist.
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular CarcinomaPhase 3<1 mi
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid TumorsPhase 1/2<1 mi
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid TumorsPhase 1<1 mi
National Liver Cancer Screening TrialPhase 4<1 mi
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP TrialPhase 3<1 mi
A Prospective Database of Infants With Cholestasis—<1 mi
Measuring Patient Reported Needs in Outpatient Liver Disease Management—<1 mi
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin ProteinPhase 3<1 mi
Primary Sclerosing Cholangitis in Children—<1 mi
Drug-Induced Liver Injury (DILI) Network Retrospective—<1 mi
RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)Phase 2<1 mi
Fibrosis Lessens After Metabolic SurgeryPhase 4<1 mi
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASHPhase 3<1 mi
Functional Assessment in Liver Transplantation—<1 mi
DILIN - Prospective Study—<1 mi
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)N/A<1 mi
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)Phase 3<1 mi
Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) TrialPhase 2<1 mi
Hepatic Impairment With Cirrhosis Due to Cholestatic Liver DiseasePhase 1<1 mi
Mediterranean Diet Versus Western Diet on Fatigue in Autoimmune Hepatitis PatientsN/A<1 mi
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This ConditionPhase 2<1 mi
A-LiNK: Improving Outcomes in Autoimmune Liver Disease—<1 mi
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver DiseasePhase 2<1 mi
Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver DiseasePhase 1<1 mi
A Trial of Post-Discharge Transitional Care for Patients With Chronic Liver DiseaseN/A<1 mi
SAMe Trial for Patients With Alcoholic CirrhosisPhase 2<1 mi
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)Phase 3<1 mi
Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)Phase 3<1 mi
A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIVPhase 2<1 mi
Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical OutcomesPhase 3<1 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.